Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and Leucovorin as First-line Treatment for Patients with Metastatic or Recurrent Colorectal Cancer.
10.3346/jkms.2007.22.3.400
- Author:
Joon Ho MOON
1
;
Jong Gwang KIM
;
Sang Kyun SOHN
;
Jin Ho BAEK
;
Yoon Young CHO
;
Yee Soo CHAE
;
Byung Min AHN
;
Shi Nae KIM
;
Soo Jung LEE
;
In Taek LEE
;
Gyu Seog CHOI
;
Soo Han JUN
Author Information
1. Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, 50 Samduck 2-ga, Jung-gu, Daegu, Korea. jkk21c@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Colorectal Neoplasms;
Oxaliplatin;
Fluorouracil;
LeucovorinZ
- MeSH:
Adolescent;
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Colorectal Neoplasms/*drug therapy/pathology;
Female;
Fluorouracil/*administration & dosage;
Humans;
Leucovorin/*administration & dosage;
Male;
Middle Aged;
Neoplasm Metastasis;
Organoplatinum Compounds/*administration & dosage;
Outpatients;
Recurrence
- From:Journal of Korean Medical Science
2007;22(3):400-404
- CountryRepublic of Korea
- Language:English
-
Abstract:
The objectives of the present study were to evaluate the efficacy and safety of an outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as the first-line treatment for patients with advanced colorectal cancer. Forty-three histologically confirmed patients with metastatic or recurrent colorectal cancer were enrolled. The chemotherapy consisted of oxaliplatin 85 mg/m2 as a 2-hr infusion on day 1, plus leucovorin 30 mg/m2 over 10 min, followed by bolus 5-fluorouracil 400 mg/m2 and an 8-hr infusion of 5-fluorouracil 600 mg/m2 on days 1 and 2 (modified FOLFOX4), all of which were administered on an outpatient basis every 2 weeks. The median age was 58 yr (range 33-72 yr), and 25 (58.1%) patients had metastatic diseases. Eventually, 39 patients were assessable for efficacy and all assessable for toxicity. Four (9.3%) complete responses and 11 (25.6%) partial responses were confirmed, giving an overall response rate of 34.9% (95% CI; 20.0-49.7%). The median time to progression and median overall survival for all patients was 6.1 months and 17.4 months, respectively. Grade 3/4 neutropenia occurred in 2 patients (4.7%) and febrile neutropenia was observed in 1 patient (2.3%). Modified FOLFOX4, an outpatient-basis regimen, was found to be well-tolerated and effective as the firstline chemotherapy in patients with advanced colorectal cancer.
